Equities Analysts Set Expectations for PolyPid Q1 Earnings

PolyPid Ltd. (NASDAQ:PYPD) – HC Wainwright reduced their Q1 2025 earnings per share estimates for PolyPid in a research note issued on Monday, April 14th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.80) per share for the quarter, down from their prior forecast of ($0.74). HC Wainwright currently has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for PolyPid’s Q2 2025 earnings at ($0.58) EPS, Q3 2025 earnings at ($0.42) EPS and FY2025 earnings at ($1.87) EPS.

Several other equities analysts also recently weighed in on PYPD. RODMAN&RENSHAW raised shares of PolyPid to a “strong-buy” rating in a research note on Tuesday, January 28th. Rodman & Renshaw assumed coverage on PolyPid in a research report on Tuesday, January 28th. They issued a “buy” rating and a $13.00 target price on the stock.

PolyPid Trading Down 0.3 %

Shares of NASDAQ:PYPD opened at $2.74 on Wednesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.31 and a quick ratio of 1.00. The business’s 50 day moving average price is $2.81 and its 200-day moving average price is $3.09. The firm has a market capitalization of $27.93 million, a price-to-earnings ratio of -0.55 and a beta of 1.28. PolyPid has a 1 year low of $2.30 and a 1 year high of $5.09.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23).

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in PYPD. J. Goldman & Co LP purchased a new position in PolyPid in the fourth quarter valued at approximately $391,000. AIGH Capital Management LLC grew its holdings in shares of PolyPid by 21.8% during the fourth quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock worth $2,509,000 after purchasing an additional 148,199 shares during the last quarter. Finally, Rosalind Advisors Inc. boosted its position in shares of PolyPid by 49.9% in the 4th quarter. Rosalind Advisors Inc. now owns 1,018,021 shares of the company’s stock valued at $3,095,000 after purchasing an additional 338,853 shares during the period. Hedge funds and other institutional investors own 26.47% of the company’s stock.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.